Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
- Author:
José Antonio LÓPEZ-GUERRERO
1
;
Ignacio ROMERO
;
Andrés POVEDA
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents, Alkylating; therapeutic use; Clinical Trials as Topic; DNA Damage; Dioxoles; administration & dosage; pharmacology; therapeutic use; Doxorubicin; administration & dosage; analogs & derivatives; Female; Humans; Neoplasm Recurrence, Local; drug therapy; Neoplasms, Glandular and Epithelial; drug therapy; Ovarian Neoplasms; drug therapy; Polyethylene Glycols; administration & dosage; Tetrahydroisoquinolines; administration & dosage; pharmacology; therapeutic use; Tumor Microenvironment
- From:Chinese Journal of Cancer 2015;34(1):41-49
- CountryChina
- Language:English
- Abstract: Epithelial ovarian cancer (OC) is a common gynecologic malignancy in women. The standard treatment for OC is maximal cytoreductive surgical debulking followed by platinum-based chemotherapy. Despite the high response rate to primary therapy, approximately 85% of patients will develop recurrent ovarian cancer (ROC). This review identifies the clinical use of trabectedin in the treatment algorithm for ROC, with specific emphasis on platinum-sensitive ROC, for which trabectedin in combination with pegylated liposomal doxorubicin has been approved as a treatment protocol. The main mechanisms of action of trabectedin at the cellular level and in the tumor microenvironment is also discussed as bases for identifying biomarkers for selecting patients who may largely benefit from trabectedin-based therapies.
